The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products--even though new technologies have increased both the cost and the medical attractiveness of those products.
Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research.
This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.
Robert B. Helms is a resident scholar at AEI.
Table of Contents
Introduction
Generics and the Producer Price Index for Pharmaceuticals
An Updated and Extended Study of the Price Growth of Prescription Pharmaceutical Preparations
Measuring Quality Change in the Market for Anti-Ulcer Drugs
The Uses and Abuses of International Price Comparisons
Industrial Policy and International Competitiveness in the Pharmaceutical Industry
R&D Productivity and Global Market Share in the Pharmaceutical Industry
The Determinants of Research Productivity in Ethical Drug Discovery
Prospects for Returns to Pharmaceutical R&D under Health Care Reform
Measuring Pharmaceutical Industry Risk and the Cost of Capital
The Effects of Research and Promotion on Rates of Return
New Uses for Old Drugs
The Leverage Principle in FDA's Regulation of Information
Costs and Benefits of Cost-Benefit Analysis in Pharmaceutical Promotion and Utilization Decisions
In Making a Killing: The Deadly Implications of the Counterfeit Drug Trade, AEI resident fellow Roger Bate analyzes the burgeoning international trade in counterfeit drugs and recommends steps that governments and law enforcement agencies could take to stop it.
Should Medicare pay for patient expenses the way automobile insurers pay for car-repair bills? In How to Fix Medicare, health economist Roger Feldman argues that a radical shift in Medicare policy is not only possible but imperative.
